FDA U.S. FOOD & DRUG ADMINISTRATION

Scheduling a Tissue Residue Analytical Method Demonstration Meeting

Background

For a new animal drug intended for use in a food-producing animal, where a tolerance will be established for residue monitoring, a practicable method is required that can accurately identify the marker residue at the tolerance concentration in the target tissue.

The requirements for the method are outlined in Guidance for Industry #3 "General Principles for Evaluating the Human Food Safety of New Animal Drugs Used in Food-Producing Animals"

The Official Method will undergo an interlaboratory method transfer trial where the method is evaluated in the drug sponsor's reference laboratory, CVM's Office of Research (OR), and two independent contract laboratories identified by the sponsor.

In special circumstances where CVM already has experience with the method, a single laboratory validation (SLV) can be performed. This would involve only the reference laboratory and OR participation in the method transfer trial.

CVM has committed to an ADUFA goal to: "Commence 90% of tissue residue method demonstrations within 120 days of completion of the 3-hour meeting process or equivalent process milestone where there is a single laboratory validation tissue residue method demonstration."

The drug sponsor should discuss with CVM the potential for SLV early in method development.

Overview of Submissions Leading to the Method Demonstration

The following are the types of submissions and outcomes generally seen for the method leading up to the method demonstration:

1. Protocol for the method validation (E submission)(optional): CVM's reply will indicate concurrence or nonconcurrence with the method validation protocol.
2. Validation report (either an H or P submission; the result of the validation protocol above): CVM's reply for an SLV will indicate if the method is acceptable to move on to the method demonstration. CVM's reply for a full-scale method trial will indicate if the method is acceptable to move on to the 3-hour meeting.
3. 3-hour meeting (Z submission): This gives the sponsor the opportunity to present the validated method and supporting data in front of ONADE and OR staff. The OR staff will assist ONADE in determining if the method is ready to move to the method demonstration and inter-laboratory transfer trial. CVM will notify the sponsor by email if the method can move to the method demonstration meeting within 14 days of the 3-hour meeting.
4. Method Demonstration meeting (Z submission): Meeting at OR where an analyst from the reference laboratory performs the method in presence of other method trial participants.

Changes at CVM to Meet the Goal

- OR has procedures in place so method demonstrations can be held closer together than was previously possible.
- An ONADE internal SOP was put in place to facilitate communication between ONADE and OR while reviewing submissions leading to the method demonstration meeting
- ONADE (working with the Project Management teams) will give more advanced notice to OR about upcoming/expected method trials.
- When a method validation is submitted, the method SOP that accompanies the validation information will be shared with OR to identify any potential problems with running the method in the OR laboratory (*e.g.*, additional equipment needs).
- Discussions about potential dates will be held internally between ONADE and OR during the validation report review, and acceptable tentative dates will be in place by the time of the 3-hour meeting.

Requesting the Method Demonstration Meeting

- CVM will communicate proposed dates to the drug sponsor after CVM agrees that the method can move to the method demonstration
- Once dates are agreed upon by the drug sponsor and CVM, the sponsor should submit a meeting request *via* eSubmitter
- On the I-Z meeting request eSubmitter template, the drug sponsor should select Method Demonstration (MD) under the "scope of meeting" question
  - eSubmitter will then request that the submitter: "Please provide the CVM Submission Number associated with the Z, H or P submission where CVM agreed that the analytical method may proceed to the method trial."
  - The reply to this question should be the 4-digit submission number of either the 3-hour meeting for full-scale method trials, or the submission containing validation data for an SLV
- CVM requests that the drug sponsor not send in the meeting request until the date has been agreed upon, and that the sponsor enter the agreed upon meeting date in the eSubmitter request for the meeting.